Efficacy and Safety of Topical Lignosus rhinocerus TM02® Extract (xLr®) Versus 1% Hydrocortisone Cream in Mild-to-moderate Atopic Dermatitis. A 6-week Split-site Pilot Study
Malaysian Journal of Dermatology · 2026
DOI: 10.4103/mjd.mjd_23_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Malaysian Journal of Dermatology, 2026. Verfasst von Rebecca Kai Jan Choong und 7 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Lignosus rhinocerus (commonly known as tiger milk mushroom) is an edible mushroom indigenous to the jungles of Asia, including Malaysia, which has anti-inflammatory, immunomodulatory, antifungal and antibacterial properties.
Aims
This study aimed to evaluate the efficacy and safety of a topical cream containing L. rhinocerus TM02 ® extract (xLr ® ) versus 1% hydrocortisone cream as a treatment for mild-to-moderate atopic dermatitis (AD). Subjects and Methods: We investigated the use of L. rhinoceros as a topical treatment option for AD by carrying out a 6-week, open-label, split-site study involving 22 patients aged ≥ 12 years. Disease severity was assessed using the Peak Pruritus Numerical Rating Scale (PNRS) and the AD Severity Index (ADSI). The occurrence of any adverse events was recorded.
Results
The study cream containing xLr ® showed a significant improvement in severity (mean ADSI 4.4 ± 2.7 at baseline to 2.1 ± 2.0 at Week 6, P = 0.010) and pruritus (mean PNRS 2.2 ± 2.2 at baseline to 1.1 ± 1.5 at Week 6, P = 0.018). These results at 6 weeks were comparable to the hydrocortisone 1% cream arm, with a reduction in mean ADSI from 4.3 ± 2.3 at baseline to 1.9 ± 2.0 ( P < 0.010) and mean PNRS from 2.3 ± 2.1 to 0.8 ± 0.8 ( P = 0.002). There was no statistical difference between the ADSI ( P = 0.445) and PNRS ( P = 0.133) of xLR ® and hydrocortisone 1% cream at the end of Week 6. No adverse events were reported. Conclusion: xLr® is a non-steroidal topical agent with comparable efficacy to 1% hydrocortisone with a potential utility in the treatment armamentarium for AD.
Zitieren
APA
Choong, R. K. J., Han, W. H., Yong, S. S., Tan, H. D., Yahya, A., Chong, S., Kwan, Z., & Fung, S. Y. (2026). Efficacy and Safety of Topical Lignosus rhinocerus TM02® Extract (xLr®) Versus 1% Hydrocortisone Cream in Mild-to-moderate Atopic Dermatitis. A 6-week Split-site Pilot Study. Malaysian Journal of Dermatology. https://doi.org/10.4103/mjd.mjd_23_25
Vancouver
Choong RKJ, Han WH, Yong SS, Tan HD, Yahya A, Chong S, et al. Efficacy and Safety of Topical Lignosus rhinocerus TM02® Extract (xLr®) Versus 1% Hydrocortisone Cream in Mild-to-moderate Atopic Dermatitis. A 6-week Split-site Pilot Study. Malaysian Journal of Dermatology. 2026. doi:10.4103/mjd.mjd_23_25
BibTeX
@article{Choong2026,
author = {Choong, Rebecca Kai Jan and Han, Winn Hui and Yong, Shin Shen and Tan, Hao Dong and Yahya, Abqariyah and Chong, Song-Haw and Kwan, Zhenli and Fung, Shin Yee},
title = {Efficacy and Safety of Topical Lignosus rhinocerus TM02® Extract (xLr®) Versus 1% Hydrocortisone Cream in Mild-to-moderate Atopic Dermatitis. A 6-week Split-site Pilot Study},
journal = {Malaysian Journal of Dermatology},
year = {2026},
doi = {10.4103/mjd.mjd_23_25}
}
EUVIMED